Loading clinical trials...
Loading clinical trials...
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)
Conditions
Interventions
lisaftoclax +BTK inhibitor
BTK inhibitor
Locations
2
United States
MD Anderson Cancer Center
Houston, Texas, United States
Kaluga Regional Clinical Research
Kaluga, Russia
Start Date
December 20, 2023
Primary Completion Date
October 20, 2025
Completion Date
October 31, 2027
Last Updated
September 18, 2025
NCT07523555
NCT07108998
NCT06319456
NCT05791409
NCT06476899
NCT05920668
Lead Sponsor
Ascentage Pharma Group Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions